Every earnings call for INDOCO — management tone, guidance, KPIs and promise tracking, quarter by quarter.
INDOCO · 5 transcripts · Healthcare · latest Q4 FY26Indoco Remedies Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Consolidated EBITDA 497 million; Standalone EBITDA Margin 14.7%. Consolidated Net Revenues grew 18.8% YoY to INR 4,559 million.
Read full transcript & analysisConsolidated EBITDA 315 million (+162% YoY); Consolidated EBITDA Margin 7.3%. Consolidated Net Revenues grew 7.9% YoY to INR 4,343 million.
Read full transcript & analysisConsolidated EBITDA ₹43 cr (+7% YoY); Consolidated EBITDA Margin 9.1% (−0% YoY). Consolidated net revenues grew 9.5% YoY to ₹471.8 crores.
Read full transcript & analysisConsolidated EBITDA Margin 4.1%. Consolidated net revenues grew 1.13% YoY to Rs. 429.1 crores.
Read full transcript & analysisConsolidated EBITDA Margin 4.1%. Consolidated net revenues grew 11.77% QoQ to ₹4,291 million.
Read full transcript & analysis